STE-FOY, QUEBEC--(MARKET WIRE)--Jul 16, 2007 -- Bioxel Pharma Inc. (CDNX:BIP.V - News) a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, announced today that it is expanding its taxane presence into Asia with the first significant paclitaxel delivery being made to the region. The paclitaxel sale was valued at $200,000.
